2. Search Result
Search Result
Results for "

CCRCC

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

2

Inhibitory Antibodies

4

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B2171A
    Carubicin hydrochloride

    Carminomycin hydrochloride; Carminomicin I hydrochloride

    		 Apoptosis Infection Cancer
    Carubicin hydrochloride is a microbially-derived compound. Carubicin hydrochloride is an effective inhibitor of VHL-defective (VHL−/−) CCRCC cell proliferation. Carubicin hydrochloride also induces apoptosis by a mechanism independent of p53 or hypoxia-inducible factor HIF2. Carubicin hydrochloride has the potential for the research of cancer diseases .
    Carubicin hydrochloride
  • HY-W013274
    CPTH2

    		Histone Acetyltransferase Apoptosis Cancer
    CPTH2 is a potent histone acetyltransferase (HAT) inhibitor. CPTH2 selectively inhibits the acetylation of histone H3 by Gcn5. CPTH2 induces apoptosis and decreases the invasiveness of a clear cell renal carcinoma (ccRCC) cell line through the inhibition of acetyltransferase p300 (KAT3B) .
    CPTH2
  • HY-W661499
    Orellanine

    		Phosphatase Cancer
    Orellanine is a fungal nephrotoxin. Orellanine is also a competitive inhibitor of alkaline phosphatase. Orellanine induces cell death in proximal tubular cells and in ccRCC cells. Orellanine can be used for research of clear cell renal cell carcinoma (ccRCC) .
    Orellanine
  • HY-B2171
    Carubicin

    Carminomycin; Carminomicin I

    		 Apoptosis Infection Cancer
    Carubicin (Carminomycin) is a microbially-derived compound. Carubicin is an effective inhibitor of VHL-defective (VHL−/−) CCRCC cell proliferation. Carubicin also induces apoptosis by a mechanism independent of p53 or hypoxia-inducible factor HIF2. Carubicin has the potential for the research of cancer diseases .
    Carubicin
  • HY-W013274A
    CPTH2 hydrochloride

    		Histone Acetyltransferase Apoptosis Cancer
    CPTH2 hydrochloride is a potent histone acetyltransferase (HAT) inhibitor. CPTH2 hydrochloride selectively inhibits the acetylation of histone H3 by Gcn5. CPTH2 hydrochloride induces apoptosis and decreases the invasiveness of a clear cell renal carcinoma (ccRCC) cell line through the inhibition of acetyltransferase p300 (KAT3B) .
    CPTH2 hydrochloride
  • HY-P99463
    Batiraxcept

    AVB-S6-500

    		 TAM Receptor Cancer
    Batiraxcept (AVB-S6-500) is a highly potent and specific AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with AXL, thereby substantially reducing AXL signaled invasion and migration of highly metastatic cells in vitro and inhibiting metastatic disease in nonclinical models of aggressive human cancers. Batiraxcept is available for studies in advanced or metastatic clear cell renal cell carcinoma (ccRCC) and platinum sensitive recurrent ovarian cancer .
    Batiraxcept
  • HY-149673
    XPW1

    		CDK Cancer
    XPW1 is a potent and selective CDK9 inhibitor with excellent activity against clear cell renal cell carcinoma (ccRCC) and low toxicity .
    XPW1
  • HY-12449
    Crenigacestat
    4 Publications Verification

    LY3039478

    		 Notch γ-secretase Cancer
    Crenigacestat (LY3039478) is an orally active Notch and γ-secretase inhibitor, with an IC50 of 1 nM in most of the tumor cell lines tested .
    Crenigacestat
  • HY-P99023
    Girentuximab

    G250; cG250

    		 Carbonic Anhydrase Cancer
    Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC) .
    Girentuximab
  • HY-161251
    SPOP-IN-2

    		Others Cancer
    SPOP-IN-2 (compound E1) is a Speckle-type POZ protein (SPOP) inhibitor with IC50 of 0.58 μM, which disrupt the SPOP-subtrate interaction and selectively inhibits proliferation of ccRCC .
    SPOP-IN-2
  • HY-125840
    Belzutifan
    3 Publications Verification

    PT2977; MK-6482

    		 HIF/HIF Prolyl-Hydroxylase Cancer
    Belzutifan (PT2977) is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. Belzutifan, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. Belzutifan is a potential treatment for clear cell renal cell carcinoma (ccRCC) .
    Belzutifan
  • HY-151341
    HIF-1/2α-IN-1

    		HIF/HIF Prolyl-Hydroxylase Cancer
    HIF-1/2α-IN-1 is an orally active HIF-2α inhibitor. HIF-1/2α-IN-1 inhibits HIF-2α activity with an IC50 value of 0.92 μM. HIF-1/2α-IN-1 also can decrease HIF-1α levels. HIF-1/2α-IN-1 can be used for the research of clear cell renal cell carcinoma (ccRCC) .
    HIF-1/2α-IN-1
  • HY-N6074
    Soyasapogenol B

    		Autophagy Apoptosis Inflammation/Immunology Cancer
    Soyasapogenol B is a component of soy that has oral activity. Soyasapogenol B promotes autophagy and apoptosis. Soyasapogenol B has anti-inflammatory, antioxidant and antitumor activities .
    Soyasapogenol B
  • HY-151344
    HIF-1/2α-IN-2

    		HIF/HIF Prolyl-Hydroxylase Cancer
    HIF-1/2α-IN-2 is an inhibitor of HIF-1/2α. HIF-1/2α-IN-2 decrease HIF-1/2α levels and induces iron starvation response by targeting Iron Sulfur Cluster Assembly 2 (ISCA2) .
    HIF-1/2α-IN-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: